EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

Clinical and Translational Allergy

Volumn 2, Issue 1, 2012, Pages

  Calderon, Moises A ^a   Demoly, Pascal ^b   Gerth Van Wijk, Roy ^c   Bousquet, Jean ^b   Sheikh, Aziz ^d   Frew, Anthony ^e   Scadding, Glenis ^f   Bachert, Claus ^g   Malling, Hans J ^h   Valenta, Rudolph ⁱ   Bilo, Beatrice ^j   Nieto, Antonio ^k   Akdis, Cezmi ^l   Just, Jocelyne ^m   Vidal, Carmen ⁿ   Varga, Eva M ^o   Alvarez Cuesta, Emilio ^p   Bohle, Barbara ⁱ   Bufe, Albrecht ^q   Canonica, Walter G ^r   Cardona, Victoria ^s   Dahl, Ronald ^t   Didier, Alain ^u   Durham, Stephen R ^v   Eng, Peter ^w   Fernandez Rivas, Montserrat ^x   Jacobsen, Lars ^y   Jutel, Marek ^z   Kleine Tebbe, Jörg ^aa   Klimek, Ludger ^ab   Lötvall, Jan ^ac   Moreno, Carmen ^ad   Mosges, Ralph ^ae   Muraro, Antonella ^af   Niggemann, Bodo ^ag   Pajno, Giovanni ^ah   Passalacqua, Giovanni ^ai   Pfaar, Oliver ^ab   Rak, Sabina ^ak   Senna, Gianenrico ^al   Senti, Gabriela ^am   Valovirta, Erkka ^an   Van Hage, Marianne ^ao   Virchow, Johannes C ^ap   Wahn, Ulrich ^aq   Papadopoulos, Nikolaos ^aj   more..

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^f ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h Rigshospitalet   (Denmark)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j OSPEDALI RIUNITI   (Italy)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l UNIVERSITY OF ZURICH   (Switzerland)

^m ARMAND TROUSSEAU HOSPITAL   (France)

ⁿ Instituto de Salud Carlos III   (Spain)

^o MEDICAL UNIVERSITY OF GRAZ   (Austria)

^p HOSPITAL RAMÓN Y CAJAL   (Spain)

^q RUHR UNIVERSITY BOCHUM   (Germany)

^r UNIVERSITY OF GENOA   (Italy)

^s HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^t AARHUS UNIVERSITY HOSPITAL   (Denmark)

^u SERVICE DE PNEUMOLOGIE   (France)

^v ROYAL BROMPTON HOSPITAL   (United Kingdom)

^w Department of Pediatrics   (Switzerland)

^x HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^y GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^z WROCLAW MEDICAL UNIVERSITY   (Poland)

^aa Allergy and Asthma Center Westend   (Germany)

^ab Centre of Rhinology and Allergology   (Germany)

^ac UNIVERSITY OF GOTHENBURG   (Sweden)

^ad HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^ae UNIVERSITY OF COLOGNE   (Germany)

^af UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^ag Pediatric Allergology and Pneumology   (Germany)

^ah UNIVERSITY OF MESSINA   (Italy)

^ai UNIVERSITY OF GENOA   (Italy)

^aj UNIVERSITY OF ATHENS   (Greece)

^ak SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^al Verona General Hospital   (Italy)

^am UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^an Suomen Terveystalo Allergy Clinic   (Finland)

^ao KAROLINSKA INSTITUTE   (Sweden)

^ap ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^aq CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Allergy; Asthma; Health economics; Immunotherapy; Quality of life; Rhinitis

Indexed keywords

ALLERGEN;

ALLERGIC DISEASE; ARTICLE; AWARENESS; CAREER; CLIMATE CHANGE; CLINICAL EFFECTIVENESS; COST CONTROL; DISEASE COURSE; DISEASE SURVEILLANCE; EUROPE; EUROPEAN; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; IMMUNOTHERAPY; INDUSTRIALIZATION; INVESTMENT; LIFESTYLE; MEDICAL CARE; MEDICAL PARAMETERS; MEDICAL RESEARCH; MEDICAL SPECIALIST; META ANALYSIS (TOPIC); NATIONAL HEALTH SERVICE; PANDEMIC; POLLUTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PRODUCTIVITY; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SOCIAL EVOLUTION; SYMPTOM; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; URBANIZATION; WELLBEING;

EID: 85006341561     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/2045-7022-2-20     Document Type: Article

References (59)

1. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.; ISAAC Phase Three Study Group. Lancet. 2006, 368 (9537): 733-743. 10.1016/S0140-6736(06)69283-0.
2. Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E: Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007, 62: 758-766. 10.1136/thx.2006.070169.
3. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, Gjomarkaj M, Forsberg B, Gunnbjornsdottir M, Minov J, Brozek G, Dahlen SE, Toskala E, Kowalski ML, Olze H, Howarth P, Krämer U, Baelum J, Loureiro C, Kasper L, Bousquet PJ, Bousquet J, Bachert C, Fokkens W, Burney P: Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in Europe. Allergy. 2012, 67: 91-98. 10.1111/j.1398-9995.2011.02709.x.
4. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen).; World Health Organization; GA(2)LEN; AllerGen. Allergy. 2008, 63 (Suppl 86): 8-160.
5. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA: The diagnosis and management of rhinitis: an updated practice parameter. Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2008, 122 (2 Suppl): S1-S84.
6. World Health Organization (WHO): Fact sheet No. 307 on Asthma. 2011
7. Punekar YS, Sheikh A: Establishing the incidence and prevalence of clinician-diagnosed allergic conditions in children and adolescents using routinely collected data from general practices. Clin Exp Allergy. 2009, 39 (8): 1209-1216. 10.1111/j.1365-2222.2009.03248.x.
8. Isolauri E, Huurre A, Salminem S, Impivaara O: The allergy epidemic extends beyond the past two decades. Clin Exp Allergy. 2004, 34: 1007-1010. 10.1111/j.1365-2222.2004.01999.x.
9. Gupta R, Sheikh A, Strachan DP, Anderson HR: Time trends in allergic disorders in the UK. Thorax. 2007, 62 (1): 91-96. 10.1136/thx.2004.038844.
10. Grize L, Gassner M, Wüthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH: Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006, 61 (5): 556-562. 10.1111/j.1398-9995.2006.01030.x.
11. Smith JA, Drake R, Simpson A, Woodcock A, Pickles A, Custovic A: Dimensions of respiratory symptoms in preschool children: population-based birth cohort study. Am J Respir Crit Care Med. 2008, 177 (12): 1358-1363. 10.1164/rccm.200709-1419OC.
12. Anandan C, Nurmatov U, van Schayck OC, Sheikh A: Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy. 2010, 65 (2): 152-167. 10.1111/j.1398-9995.2009.02244.x.
13. Siroux V, Boudier A, Anto JM, Cazzoletti L, Accordini S, Alonso J: Quality-of-life and asthma-severity in general population asthmatics: results of the ECRHS II study. Allergy. 2008, 63 (5): 547-554. 10.1111/j.1398-9995.2008.01638.x.
14. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A: Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007, 120: 381-387. 10.1016/j.jaci.2007.03.034.
15. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M: Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006, 117: 158-162. 10.1016/j.jaci.2005.09.047.
16. Stuck BA, Czaijkowski J, Hagner AE, Klimek L, Verse T, Hörmann K: Changes in daytime sleepiness, quality of life, and objective sleep patterns in seasonal allergic rhinitis: a controlled clinical trial. J Allergy Clin Immunol. 2004, 113: 663-668. 10.1016/j.jaci.2003.12.589.
17. Baiardini I, Braido F, Tarantini F, Porcu A, Bonini S, Bousquet PJ: ARIA-suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN review. Allergy. 2008, 63 (6): 660-669. 10.1111/j.1398-9995.2008.01649.x.
18. Bachert C, Bousquet J, Canonica GW, Durham SR: The XPERTTM study group. XPERTTM Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004, 114: 838-844. 10.1016/j.jaci.2004.05.070.
19. Virchow JC, Kay S, Demoly P, Mullol J, Canonica W, Higgins V: Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients - an observational, cross sectional study in four countries in Europe. J Med Econ. 2011, 14 (3): 305-314. 10.3111/13696998.2011.576039.
20. Wertz DA, Pollack M, Rodgers K, Bohn RL, Sacco P, Sullivan SD: Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Ann Allergy Asthma Immunol. 2010, 105 (2): 118-123. 10.1016/j.anai.2010.05.009.
21. Lefevre F, Moreau D, Sémon E, Kalaboka S, Annesi-Maesano I, Just J: Maternal depression related to infant's wheezing. Pediatr Allergy Immunol. 2011, 22 (6): 608-613. 10.1111/j.1399-3038.2011.01155.x.
22. Gupta R, Sheikh A, Strachan DP, Anderson HR: Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004, 34 (4): 520-526. 10.1111/j.1365-2222.2004.1935.x.
23. Anandan C, Gupta R, Simpson CR, Fischbacher C, Sheikh A: Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases. J R Soc Med. 2009, 102 (10): 431-442. 10.1258/jrsm.2009.090027.
24. European Respiratory Society (ERS): European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. 2003
25. Accordini S, Corsico A, Cerveri I, Gislason D, Gulsvik A, Janson C: The socio-economic burden of asthma is substantial in Europe. Allergy. 2008, 63 (1): 116-124.
26. Sullivan SD, Turk F: An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy. 2008, 63: 670-684. 10.1111/j.1398-9995.2008.01723.x.
27. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C: Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy. 2005, 60: 788-794. 10.1111/j.1398-9995.2005.00820.x.
28. Zuberbier T, Lötvall J: Allergies have a socio-economic impact. European academy of allergology and clinical immunology, annual meeting 2008. Allergy. 2008, 63 (Suppl. 84): 280-
29. Reed SD, Lee TA, McCrory DC: The economic burden of allergic rhinitis: a critical evaluation of the literature. PharmacoEconomics. 2004, 22 (6): 345-361. 10.2165/00019053-200422060-00002.
30. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen PB: Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy. 2008, 63: 1624-1629. 10.1111/j.1398-9995.2008.01743.x.
31. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ: Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006, 354 (19): 1985-1997. 10.1056/NEJMoa051378.
32. Marinho S, Simpson A, Custovic A: Allergen avoidance in the secondary and tertiary prevention of allergic diseases: does it work?. Prim Care Respir J. 2006, 15 (3): 152-158. 10.1016/j.pcrj.2006.02.005.
33. Phan H, Moeller ML, Nahata MC: Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009, 69 (18): 2541-2576. 10.2165/9884960-000000000-00000.
34. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A: IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006, 368 (9537): 754-762. 10.1016/S0140-6736(06)69285-4.
35. White P, Smith H, Baker N, Davis W, Frew A: Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?. Clin Exp Allergy. 1998, 28 (3): 266-270. 10.1046/j.1365-2222.1998.00237.x.
36. Allen DB: Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr. 2006, 53: 101-110. 10.1016/j.yapd.2006.04.006.
37. Layton D, Wilton L, Boshier A, Cornelius V, Harris S, Shakir SA: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf. 2006, 29 (10): 897-909. 10.2165/00002018-200629100-00007.
38. Passalacqua G, Bousquet PJ, Carlsen KH, Kemp J, Lockey RF, Niggemann B, Pawankar R, Price D, Bousquet J: ARIA update: I-Systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006, 117 (5): 1054-1062. 10.1016/j.jaci.2005.12.1308.
39. Council of the European Union: Review of the EU Sustainable Developmental Strategy (EU SDS): Renewed Strategy. 2006, 10917/06
40. Abramson MJ, Puy RM, Weiner JM: Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010, 4 (8): CD001186-
41. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007, 24 (1): CD001936-
42. Radulovic S, Calderon MA, Wilson D, Durham S: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010, 8 (12): CD002893-
43. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR: Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011, 41 (9): 1263-1272. 10.1111/j.1365-2222.2011.03835.x.
44. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999, 341 (7): 468-475. 10.1056/NEJM199908123410702.
45. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J. Allergy Clin Immunol. 2010, 125 (1): 131-138. 10.1016/j.jaci.2009.10.035.
46. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R: SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012, 129 (3): 717-725. 10.1016/j.jaci.2011.12.973.
47. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C, The PAT investigator group: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, 62 (8): 943-948. 10.1111/j.1398-9995.2007.01451.x.
48. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006, 61 (2): 198-201. 10.1111/j.1398-9995.2006.01011.x.
49. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, Burastero SE, Calori G, Benetti L, Bonazza P, Puccinelli P, Parmiani S, Bernardini R, Vierucci A: Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004, 114 (4): 851-857. 10.1016/j.jaci.2004.07.012.
50. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G: Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010, 126 (5): 969-975. 10.1016/j.jaci.2010.08.030.
51. Canonica GW, Bousquet J, Casale T: Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009, 64 (Suppl 91): 1-59.
52. Noon L, Cantab BC: Prophylactic inoculation against hay fever. Lancet. 1911, 177 (4580): 1572-1573. 10.1016/S0140-6736(00)78276-6.
53. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998, 102 (4 Pt 1): 558-562.
54. Passalacqua G, Compalati E, Canonica GW: Advances in allergen-specific immunotherapy. Curr Drug Targets. 2009, 10 (12): 1255-1262. 10.2174/138945009789753237.
55. Bousquet PJ, Calderón MA, Demoly P, Larenas D, Passalacqua G, Bachert C, Brozek J, Canonica GW, Casale T, Fonseca J, Dahl R, Durham SR, Merk H, Worm M, Wahn U, Zuberbier T, Schünemann HJ, Bousquet J: The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol. 2011, 127 (1): 49-56. 10.1016/j.jaci.2010.09.017.
56. Bousquet J, Schünemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB, Demoly P, Durham S, Carlsen KH, Malling HJ, Passalacqua G, Simons FE, Anto J, Baena-Cagnani CE, Bergmann KC, Bieber T, Briggs AH, Brozek J, Calderon MA, Dahl R, Devillier P, Gerth van Wijk R, Howarth P, Larenas D, Papadopoulos NG, Schmid-Grendelmeier P, Zuberbier T: How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy. 2011, 66 (6): 765-774. 10.1111/j.1398-9995.2011.02590.x.
57. Calderón M, Cardona V, Demoly P: EAACI 100 Years of Immunotherapy Experts Panel. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy. 2012, 67 (4): 462-476. 10.1111/j.1398-9995.2012.02785.x.
58. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P: Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011, 127 (1): 30-38. 10.1016/j.jaci.2010.08.024.
59. Jacobsen L, Wahn U, Bilo MB: Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy. Clin Transl Allergy. 2012, 2: 8-10.1186/2045-7022-2-8.